Inpatient treatment for osteoporosis in patients with new fragility fractures

Autor: Suarez Barreto, Daniel Mauricio, Carreño Leal, Hernán
Přispěvatelé: Beltrán, Adriana
Jazyk: Spanish; Castilian
Rok vydání: 2016
Předmět:
Zdroj: 1. Jennings LA, Auerbach AD, Maselli J, Maselli J. Missed Opportunities for Osteoporosis Treatment in Patients Hospitalized for Hip Fracture. J Am Geriatr Soc. 2010.
2. Organization mundial de la Salud. Prevention and management of Osteoporosis. 2003.
3. Yang, Y, K. Soong & K.-S. Tsai & H.-Y. Huang & R.-S. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Osteoporos Int. 2013.
4. Solomon DH, Johnston SS, Boytsoy NN, McMorrow D, Lane JM. Osteoporosis Medication Use After Hip Fracture in U.S.Patients Between 2002 and 2011. Journal of Bone and Mineral Research. 2014.
5. Koo, Y.-K. Lee : B.-H. Yoon : K.-H. Incidence of second hip fracture and compliant use of bisphosphonate. International Osteoporosis Foundation and National Osteoporosis Foundation. 2013.
6. Petrella RJ, Jones TJ. Do patients receive recommended treatment of osteoporosis following hip fracture in primary care?. BMC Family Practice. 2006.
7. Quintero MA. Presentación y diagnóstico clínico de la osteoporosis. Asocioación Colombiana de Endocrinología. Osteoporosis. 2011.
8. Group, Report of a WHO Study. World Health Organization Study Group on Assessment of Fracture Risk and Its Application to Screening and Postmenopausal Osteoporosis.1994.
9. World Health Organization. The World Health Report 1997. 1997.
11. Melton LJ III. Epidemiology of fractures, chapter 10. Riggs BL, Melton LJ III eds. Philadelphia : Lippincott Reven Publishers; 1995.
12. Annie WK, Tao Fan, Ling Xu, Wei BX, Park HIl, Hak Sun Kim, Siew Pheng Chan. Factors influencing diagnosis and treatment of osteoporosis after a fragility fracture among postmenopausal women in Asian countries: a retrospective study. BMC Women's Health. 2013.
13. Ardila E. Epidemiología de la Osteoporosis. Asociación Colombiana de Endocrinología. Osteoporosis. Bogotá : s.n., 2011.
14. Kanis J. Osteoporosis. Blackwell Science Ltd. 1996.
15. Barze US, Osteoporosis: Tomando un aire fresco. 1996.
16. Talero AP. Fisiopatología del hueso y de la osteoporosis. Asociación Colombiana de Endocrinología. Osteoporosis. 2011.
17. Pickard LA, Fraser & G. Ioannidis & J. D. Adachi L. Fragility fractures and the osteoporosis care gap in women:the Canadian Multicentre Osteoporosis Study. International Osteoporosis Foundation and National Osteoporosis Foundation. 2010.
18.Rabenda V, Vanoverloop J, Fabri V, RafMertens, MD, Sumkay F, PhD,. Low Incidence of Anti-Osteoporosis Treatment After Hip Fracture. JBJS. 2008.
19. Fast Facts on Osteoporosis. National Institute of Arthritis, Musculoskeletal and Skin Diseases. Apr 13; 2009.
20. Clinician's Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation. Apr 13; 2009.
21. Palacios S, Sanchez R, Neyro JL, et al. Knowledge and compliance from patients with postmenopausal osteoporosis treatment. Menopause Int. 2009 Sep;15(3):113–119.
22. Chennuru S, Koduri J, Baumann MA. Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid. Intern Med J. 2008 Aug;38(8):635–637.
23. ISCD Bone Densitometry Course for Clinician Syllabus Editors. Brunder, Jan. 2006.
24. Muñoz TM, Varsavsky M, Aviles P, MD. Osteoporosis. Definición. Epidemiologia. Rev Osteoporosis Metab Miner 2010; (3): 5-7.
25. Kennel KA, Drake MT. Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management. Mayo Clinic Proceeding. 2009 Jul; 84(7) 632-638.
26. Susan M, MD. What is the optimal duration of bisphosphonate therapy? cleveland clinic journal of medicine. 2011 Sep; 78(9): 619-630.
27. Reginster JY, Felsenberg D, Boonnen S, Diez-Perez A, Rizzoli R, Brandi ML, et al. . Effects of Long-Term Strontium Ranelate Treatment on the Risk of Nonvertebral and Vertebral Fractures in Postmenopausal Osteoporosis. ARTHRITIS & RHEUMATISM 2008 jun; 58(6): 1687–1695.
28. Pallan S, Rahman OM, Khan AA. Diagnosis and management of primary hyperparathyroidism. BMJ. 2012 Mar; 344: 1-8.
29. Tannenbaum C, Clark J, Schwartzman K, Wallenstein S, Lapinski R, Meier D, et al. Yield of Laboratory Testing to Identify Secondary Contributors to Osteoporosis in Otherwise Healthy Women. J Clin Endocrinol Metab. 2002; 87 (10): 4431–4437.
30. Bischoff-Ferrari HA, Willett CW, Endel OJ, Meunier JP, Lyons AR, Jackson RD, et al. A Pooled Analysis of Vitamin D Dose Requirements for Fracture Prevention. Nejm.org. 2012 july 5; 367:40-49.
31.Lewiecki ME, Bilezikian PJ, Khosla DJ, McClung RM, MillerDP, Watt BN. Osteoporosis Update From the 2010 Santa Fe Bone Symposium. Journal of Clinical Densitometry: Assessment of Skeletal Health. 2011; 14, (1): 1-21.
32. Hodsman BA, Bauer CD, Dempster WD, Dian L, Hanley AD, Harris TS, et al. Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use. Endocrine Reviews. 2005 mar 15; 26(5):688 –703.
33. Peris AP, Martínez-Ferrer BA, Monegal CA, Martínez de Osaba MJ, Nuria Guañabns. 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis. Bone 2012;51: 54–58.
34 Samuel Vasikaran, Cyrus Cooper, Richard Eastell, Andrea Griesmacher, Howard A. Morris, Tommaso Trenti, et al. International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis. Clin Chem Lab Med 2011;49(8):1271–1274.
35. Base de datos de Historia Clínica del Hospital Universitario Clínica San Rafael
Popis: Las fracturas por fragilidad son aquellas que ocurren por un trauma de baja energía en personas con densidad mineral ósea disminuida para la edad. Se pretendió conocer la tasa de inicio de tratamiento intrahospitalario para osteoporosis en sujetos con fracturas nuevas por fragilidad. Metodología: Se realizó un estudio transversal incluyendo un grupo de pacientes atendidos en la institución por fracturas nuevas por fragilidad, y establecer factores asociados al no inicio de tratamiento intrahospitalario, al riesgo de necesidad de hospitalización y riesgo de muerte. Resultados: Se escogieron 180 pacientes mediante un muestreo aleatorio. El grupo de edad con mayor frecuencia de fracturas fue entre 70 y 74 años No hay factores asociados al no inicio de tratamiento intrahospitalario ni a estancia hospitalaria, el factor asociado a muerte con resultados estadísticamente significativo fue la edad mayor a 80 años (p 0,01). Resto de factores no mostraron asociación. Discusión: Actualmente en Colombia no se siguen las guías nacionales de inicio de tratamiento intrahospitalario en osteoporosis al detectar pacientes con fracturas por fragilidad. Se requiere concientizar al personal de salud para manejo oportuno e interdisciplinario. Fragility fractures are those that occur by low energy trauma in people with decreased bone mineral density due to their age. It was intended to know the rate of onset of hospital treatment for osteoporosis in patients with the onset of fragility fractures. Methodology: A descriptive study with analytical component was performed including a group of patients treated at the institution for new fragility fractures, and we establish associated factors to non-initiation of hospital treatment, the risk of requiring hospitalization and mortality. Results: 180 patients were selected by random sampling. The age group with the highest frequency of fractures was between 70 and 74. The factor associated mortality was the age older than 80 years old (p 0.01). Other factors showed no association. Discussion: Currently in Colombia, there are guidelines aimed to detect osteoporosis patients at the hospital to start early treatment in patients with fragility fractures and they are not being followed. There is a special need to aware all health personnel for a timely and interdisciplinary management of this pathology.
Databáze: OpenAIRE
Externí odkaz: